A solitary fibrous tumor in the pelvic cavity of a patient with Doege-Potter syndrome: a case report
- 115 Downloads
A solitary fibrous tumor (SFT) is a mesenchymal lesion, which commonly develops in the thorax. Non-islet cell hypoglycemia is a rare paraneoplastic phenomenon caused by an extra-pancreatic tumor. We report a rare case of a pelvic SFT with severe hypoglycemia, which was considered to be Doege-Potter syndrome.
A 72-year-old man was referred to our hospital for treatment of hypoglycemia and a large pelvic tumor. His blood glucose level was 52 mg/dl; serum insulin level, 1.0 μIU/ml; C-peptide level, 0.2 ng/ml; and insulin-like growth factor-I (IGF-I) level, 31 ng/ml. Contrast-enhanced computed tomography (CT) showed a 13-cm mass in the pelvic cavity. Magnetic resonance imaging (MRI) revealed a lobulated tumor with iso- and high-intensity areas combined in T2-weighted images. No clear invasion to any adjacent organs was identified. The tumor was resected, and hypoglycemic symptoms disappeared immediately. Pathological diagnosis was an SFT with malignant potential that secreted IGF-II and caused hypoglycemia. There has been no tumor recurrence during the 1 year of follow-up.
Non-islet cell tumor hypoglycemia should be considered in the differential diagnosis of patients presenting with tumors and hypoglycemia.
KeywordsSolitary fibrous tumor Hypoglycemia Pelvic
Insulin-like growth factor
Magnetic resonance imaging
Nerve growth factor-inducible A binding protein 2
Non-islet cell tumor hypoglycemia
Positron emission tomography
Solitary fibrous tumor
Signal transducers and activators of transcription 6
Solitary fibrous tumor (SFT) was first reported by Klemperer and Rabin in 1931 as a lesion that originated in the pleura . However, SFTs are now mesenchymal tumors and develop in various anatomic locations. Approximately 80% of SFTs are located in the thoracic cavity . Among extra-thoracic SFTs, the occurrence of a primary SFT in the pelvic cavity is rare, with a reported incidence of 16% among extra-thoracic SFTs [3, 4]. The incidence of SFT is 2.8 per 100,000 people , the age onset of SFT is around 50–60 years, and the incidence among males and females is nearly equal . Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic condition caused by an extra-pancreatic tumor. NICTH is observed in only 4% of thoracic SFTs, and this condition is referred to as Doege-Potter syndrome [4, 7]. Hypoglycemia develops due to the production of insulin-like growth factor (IGF)II by the tumor. We report a case of pelvic SFT with Doege-Potter syndrome.
A 72-year-old man was admitted to the emergency department for a hypoglycemic attack. The computed tomography (CT) scan detected a large tumor in the pelvic cavity, and he was referred to our hospital for closer examination. The patient had no relevant medical history and was not on any medication. On admission, his blood glucose level was 52 mg/dl (normal range 70–109 mg/dl); serum insulin level, 1.0 μIU/ml (normal range 3–15 μIU/ml); C-peptide level, 0.2 ng/ml (normal range 0.43–2.35 ng/ml), and IGF-I level, 31 ng/ml (normal range 58–198 ng/ml).
Hypoglycemia was observed despite continuous glucose infusion, and glucocorticoid administration was initiated prior to tumor resection. The tumor was located retroperitoneally, fed by the superior vesical artery, and was completely excised. Operation time was 388 min, and intraoperative blood loss was 1410 ml.
The postoperative course was uneventful, and hypoglycemic symptoms disappeared immediately after surgery. There has been no tumor recurrence during the 1 year of follow-up.
SFTs are typically benign, but they can be malignant, particularly if they become large or in cases of repeated recurrence. Approximately 12–22% of SFTs are found to be malignant . In NICTH cases, however, the frequency of malignancy was 60% . This suggested that SFTs with NICTH were more likely to be malignant. NICTH is observed in 4% of thoracic SFTs, and only nine cases of pelvic SFT with hypoglycemia have been reported in the literature [8, 9, 10, 11, 12, 13, 14, 15, 16].
The 2013 WHO classification of soft tissue tumors defines malignancy as hypercellular, mitotically active (> 4 mitoses/10 HPF) tumors with cytological atypia, tumor necrosis, and/or infiltrative margins . The present case was diagnosed as malignant because of a high mitosis rate and tumor necrosis.
In 2013, recurrent nerve growth factor-inducible A binding protein-2 (NAB2) and signal transducers and activators of transcription-6 (STAT6) gene fusion were identified in SFT by whole exome sequencing . A strong nuclear STAT6 signal was detected immunohistochemically as a result of the presence of the NAB2-STAT6 fusion gene, which could be helpful in diagnosing SFT. In addition, CD34, Bcl-2, vimentin, and S100 expression were often observed in SFT .
NICTH is a rare paraneoplastic phenomenon found mainly in large mesenchymal tumors such as SFT, fibrosarcoma, mesothelioma, gastrointestinal stromal tumor, and hemangiopercytoma . Doege and Potter first described NICTH in patients with SFT, and few systemic studies have been published about this condition because of its rare incidence. NICTH-causing tumors produce and release IGF-II into circulation, which has a high affinity for the insulin receptor. Normally, IGF-II forms a trimer by binding to IGF-binding proteins; thus the trimer does not pass from the circulation to the extracellular space. In NICTH, the tumor produces high molecular weight IGF-II, which has a low affinity for IGF binding proteins. As a high molecular weight IGF-II cannot form trimer, it exists in a free form in serum. Free IGF-II easily pass through capillaries and it reach the insulin receptor in the target cell . In this way, high molecular weight IGF-II witch the tumor produce causes hypoglycemia. Serum levels of IGF-II are either normal or elevated in the standard detection method, and quantification of tumor-related high molecular weight IGF-II levels is difficult. Immunoblot analysis of IGF-II is more accurate for establishing diagnosis, but these procedures often are not feasible in routine clinical settings. In clinical practice, the possibility of NICTH secondary to IGF-II is suggested by low blood glucose, with suppressed levels of serum insulin, IGF-I, C-peptide, and growth hormone [19, 21].
Complete tumor resection was reported to be the definitive treatment of SFT. Radiotherapy or chemotherapy is often applied to unresectable or metastatic tumors. However, SFTs are considered relatively chemoresistant, and there are no standard chemotherapeutic regimens. Resectability remains the most important prognostic factor . Preoperative percutaneous embolization was reported to reduce tumor volume and intraoperative blood loss, but the effect is not confirmed .
We reported a rare case of NICTH of SFT in the pelvic cavity. When a tumor with hypoglycemia is detected, the possibility of NICTH should be considered.
None of the authors received any funding.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
YW and KO conceived this case presentation and drafted the manuscript. YA, JU, HS, EA, TK, MO, KK, HU, and YS participated in the design of this case presentation. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Informed consent was obtained from the patient for publication of this case report.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Klemperer P, Rabin CB. Primary neoplasm of the pleura; a report of five cases. Arch Pathol. 1931;11:385–412.Google Scholar
- 4.Han G, Zhang Z, Shen X, et al. Doege-Potter syndrome a review of the literature including a new case report. Medicine. 2017;96:27.Google Scholar
- 15.Krishnan L, Clark J. Non-islet cell tumor hypoglycaemia. BMJ Case Rep. 2011;3:2011.Google Scholar
- 17.CDM F, Bridge JA, Lee JC. Extrapleural solitary fibrous tumor. World Health Organization Classification of Tumors of Soft Tissue and Bone. Lyon: IARC Press; 2013. p. 81.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.